DASTYCH, Milan, Ondřej WIEWIORKA and Miroslava BEŇOVSKÁ. Ethamsylate (Dicynone®) Interference in Determination of Serum Creatinine, Uric Acid, Triglycerides, and Cholesterol in Assays Involving the Trinder Reaction; In Vivo and In Vitro. Clinical Laboratory. Heidelberg: Clinical Laboratory Publications, 2014, vol. 60, No 8, p. 1373-1376. ISSN 1433-6510. Available from: https://dx.doi.org/10.7754/Clin.Lab.2013.130902.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Ethamsylate (Dicynone®) Interference in Determination of Serum Creatinine, Uric Acid, Triglycerides, and Cholesterol in Assays Involving the Trinder Reaction; In Vivo and In Vitro
Authors DASTYCH, Milan (203 Czech Republic, guarantor, belonging to the institution), Ondřej WIEWIORKA (203 Czech Republic) and Miroslava BEŇOVSKÁ (203 Czech Republic, belonging to the institution).
Edition Clinical Laboratory, Heidelberg, Clinical Laboratory Publications, 2014, 1433-6510.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10600 1.6 Biological sciences
Country of publisher Germany
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 1.129
RIV identification code RIV/00216224:14110/14:00076245
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.7754/Clin.Lab.2013.130902
UT WoS 000342857800015
Keywords in English trinder reaction; interference; ethamsylate
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 19/10/2015 15:13.
Abstract
Background: The aim of our research was the quantification of interfering properties of the haemostatic drug Dicynone® (ethamsylate) in serum creatinine, uric acid, cholesterol, and triglyceride assays using the Trinder reaction. Methods: Blood from patients was collected before and 15 minutes after administration of 500 mg Dicynone® dose i.v. and the above mentioned analytes were quantified using Roche assays (Cobas 8000). In our in vitro experiment, we measured concentrations of the analytes in pooled serum aliquots with final concentrations of Dicynone® additions 0, 30, 60, 150, and 300 mg/L. Aliquots with 60 mg/L Dicynone® were also measured at 2, 6, and 8 hours after initial measurement when stored in 22°C and 4°C for comparison. Results: Concentrations of the measured analytes in samples from patients administered with a 500 mg dose of Dicynone® were lower in all cases (n = 10) when compared to values in samples taken immediately before treatment. The in vitro samples showed that considerable negative interference occurred even with the low concentrations of Dicynone® additions (30 and 60 mg/L), showing the strongest negative interference in creatinine values, followed by uric acid, triglycerides, and cholesterol. Using in vitro samples, we showed strong time and temperature dependence on Dicynone® interference. Conclusions: We found and proved significant negative interference of the drug Dicynone® (ethamsylate) in the clinical analysis of blood using in vivo and in vitro experiments. Furthermore, we observed a change of this effect in serum matrix over time and at different storage temperatures.
PrintDisplayed: 27/7/2024 13:47